US4898732A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
Assignee: Clinipad Corp
•
Filing: 1988-05-04
•
Granted: 1990-02-06
•
Expires: 2008-05-04
Abstract
Abstract A method of inhibiting tumor growth in a patient which comprises administering to the patient an effective dose of a pharmaceutical antagonist of the renin-angiotensin system of the patient.
Inventors
- 👤 Leonardo A. Fernandez
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 16:53
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/405; A61K38/00; A61K38/16; A61K38/55; A61K38/553; A61K38/556
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
66 words
The method of implanting in a patient a controlled-release member, said member containing and releasing in controlled manner an effective dose a member selected from the group consisting of enalapril maleate, catapril and seralasin acetate, of a pharmaceutical antagonist of the renin-angiotensin system of said patient, whereby the growth of vascularization in said patient at least in an area adjacent said implanted controlled-release member is inhibited.
Claim 2
Independent Claim
66 words
The method of implanting in a patient a controlled-release member, said member containing and releasing in controlled manner an effective dose a member selected from the group consisting of enalapril maleate, catapril and seralasin acetate, of a pharmaceutical antagonist of the renin-angiotensin system of said patient, whereby the growth of vascularization in said patient at least in an area adjacent said implanted controlled-release member is inhibited.
Claim 3
Dependent Claim
16 words
The method of claim 1, in which said controlled-release member is implanted at a tumor site.
Claim 4
Dependent Claim
13 words
The method of claim 2 in which said pharmaceutical antagonist is saralasin acetate.
Claim 5
Dependent Claim
19 words
The method of claim 2 in which said pharmaceutical antagonist is an antagonist to the action of angiotensin II.
Claim 6
Dependent Claim
19 words
The method of claim 2 in which said pharmaceutical antagonist inhibits the conversion of angiotensin I to angiotensin II.
Claim 7
Dependent Claim
13 words
The method or claim 2 in which said pharmaceutical antagonist is enalapril maleate.
Claim 8
Dependent Claim
12 words
The method of claim 2 in which said pharmaceutical antagonist is captopril.
References Cited (Backward Citations)
US3932624A
Cited
US4416595A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-02-05 | 1993-08-07 | 1994-02-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-02-05 | 1997-08-07 | 1998-02-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-02-05 | 2001-08-07 | 2002-02-06 | $7700.00 | Window Closed / Lapsed |